.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Daiichi Sankyo
Moodys
Baxter
AstraZeneca
Fuji
Cipla
Federal Trade Commission
Johnson and Johnson

Generated: December 12, 2017

DrugPatentWatch Database Preview

M.V.I.-12 LYOPHILIZED Drug Profile

« Back to Dashboard

When do M.v.i.-12 Lyophilized patents expire, and when can generic versions of M.v.i.-12 Lyophilized launch?

M.v.i.-12 Lyophilized is a drug marketed by Teligent Pharma Inc and is included in one NDA.

The generic ingredient in M.V.I.-12 LYOPHILIZED is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e. There are six drug master file entries for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e profile page.

Summary for M.V.I.-12 LYOPHILIZED

You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS NOT NULL' at line 1
US Patents:0
Applicants:1
NDAs:1
Clinical Trials: 53